<?xml version='1.0' encoding='utf-8'?>
<document id="26400679"><sentence text="Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon."><entity charOffset="49-61" id="DDI-PubMed.26400679.s1.e0" text="esomeprazole" /><entity charOffset="66-79" id="DDI-PubMed.26400679.s1.e1" text="phenprocoumon" /><pair ddi="false" e1="DDI-PubMed.26400679.s1.e0" e2="DDI-PubMed.26400679.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s1.e0" e2="DDI-PubMed.26400679.s1.e1" /></sentence><sentence text="It is established that omeprazole increases (R)+ warfarin levels with around 10 %"><entity charOffset="23-33" id="DDI-PubMed.26400679.s2.e0" text="omeprazole" /></sentence><sentence text=" Whether (es)omeprazole also increase the plasma levels of acenocoumarol or phenprocoumon is still uncertain"><entity charOffset="9-23" id="DDI-PubMed.26400679.s3.e0" text="(es)omeprazole" /><entity charOffset="59-72" id="DDI-PubMed.26400679.s3.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.26400679.s3.e0" e2="DDI-PubMed.26400679.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s3.e0" e2="DDI-PubMed.26400679.s3.e1" /></sentence><sentence text=" We analyzed whether addition of (es)omeprazole to acenocoumarol or phenprocoumon increases the international normalized ratio (INR) levels and the risk of overanticoagulation"><entity charOffset="33-47" id="DDI-PubMed.26400679.s4.e0" text="(es)omeprazole" /><entity charOffset="51-64" id="DDI-PubMed.26400679.s4.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.26400679.s4.e0" e2="DDI-PubMed.26400679.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s4.e0" e2="DDI-PubMed.26400679.s4.e1" /></sentence><sentence text="" /><sentence text="We analyzed all hospital admissions in four teaching hospitals" /><sentence text=" Patients who used coumarins and pantoprazole or (es)omeprazole simultaneously for at least four consecutive days were included in the study"><entity charOffset="19-28" id="DDI-PubMed.26400679.s7.e0" text="coumarins" /><entity charOffset="33-45" id="DDI-PubMed.26400679.s7.e1" text="pantoprazole" /><entity charOffset="49-63" id="DDI-PubMed.26400679.s7.e2" text="(es)omeprazole" /><pair ddi="false" e1="DDI-PubMed.26400679.s7.e0" e2="DDI-PubMed.26400679.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s7.e0" e2="DDI-PubMed.26400679.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26400679.s7.e0" e2="DDI-PubMed.26400679.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26400679.s7.e1" e2="DDI-PubMed.26400679.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26400679.s7.e1" e2="DDI-PubMed.26400679.s7.e2" /></sentence><sentence text=" We analyzed the highest INR level and whether patients had an INR level above six" /><sentence text=" We compared patients using omeprazole or esomeprazole with patients using pantoprazole, because for pantoprazole, no interaction has been reported"><entity charOffset="28-38" id="DDI-PubMed.26400679.s9.e0" text="omeprazole" /><entity charOffset="42-54" id="DDI-PubMed.26400679.s9.e1" text="esomeprazole" /><entity charOffset="75-87" id="DDI-PubMed.26400679.s9.e2" text="pantoprazole" /><entity charOffset="101-113" id="DDI-PubMed.26400679.s9.e3" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e0" e2="DDI-PubMed.26400679.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e0" e2="DDI-PubMed.26400679.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e0" e2="DDI-PubMed.26400679.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e0" e2="DDI-PubMed.26400679.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e1" e2="DDI-PubMed.26400679.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e1" e2="DDI-PubMed.26400679.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e1" e2="DDI-PubMed.26400679.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e2" e2="DDI-PubMed.26400679.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26400679.s9.e2" e2="DDI-PubMed.26400679.s9.e3" /></sentence><sentence text="" /><sentence text="We analyzed 5747 admissions with 4540 patients using one of the drug combinations" /><sentence text=" For acenocoumarol (4578 admissions), no significant differences were found between users of esomeprazole, omeprazole, and pantoprazole"><entity charOffset="5-18" id="DDI-PubMed.26400679.s12.e0" text="acenocoumarol" /><entity charOffset="93-105" id="DDI-PubMed.26400679.s12.e1" text="esomeprazole" /><entity charOffset="107-117" id="DDI-PubMed.26400679.s12.e2" text="omeprazole" /><entity charOffset="123-135" id="DDI-PubMed.26400679.s12.e3" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e0" e2="DDI-PubMed.26400679.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e0" e2="DDI-PubMed.26400679.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e0" e2="DDI-PubMed.26400679.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e0" e2="DDI-PubMed.26400679.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e1" e2="DDI-PubMed.26400679.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e1" e2="DDI-PubMed.26400679.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e1" e2="DDI-PubMed.26400679.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e2" e2="DDI-PubMed.26400679.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26400679.s12.e2" e2="DDI-PubMed.26400679.s12.e3" /></sentence><sentence text=" For phenprocoumon (1169 admissions), the highest INR measured was significantly higher in users of esomeprazole than in users of pantoprazole (4"><entity charOffset="100-112" id="DDI-PubMed.26400679.s13.e0" text="esomeprazole" /><entity charOffset="130-142" id="DDI-PubMed.26400679.s13.e1" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.26400679.s13.e0" e2="DDI-PubMed.26400679.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s13.e0" e2="DDI-PubMed.26400679.s13.e1" /></sentence><sentence text="7 versus 4" /><sentence text="3; p = 0" /><sentence text="035)" /><sentence text=" No significant difference was found with omeprazole versus pantoprazole (4"><entity charOffset="42-52" id="DDI-PubMed.26400679.s17.e0" text="omeprazole" /><entity charOffset="60-72" id="DDI-PubMed.26400679.s17.e1" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.26400679.s17.e0" e2="DDI-PubMed.26400679.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s17.e0" e2="DDI-PubMed.26400679.s17.e1" /></sentence><sentence text="3 versus 4" /><sentence text="3; p = 0" /><sentence text="66)" /><sentence text=" A non-significant association was found between the esomeprazole dose and the highest INR level (p = 0"><entity charOffset="53-65" id="DDI-PubMed.26400679.s21.e0" text="esomeprazole" /></sentence><sentence text="055)" /><sentence text=" The risk of an INR above six did not differ significantly between esomeprazole and pantoprazole (27"><entity charOffset="67-79" id="DDI-PubMed.26400679.s23.e0" text="esomeprazole" /><entity charOffset="84-96" id="DDI-PubMed.26400679.s23.e1" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.26400679.s23.e0" e2="DDI-PubMed.26400679.s23.e0" /><pair ddi="false" e1="DDI-PubMed.26400679.s23.e0" e2="DDI-PubMed.26400679.s23.e1" /></sentence><sentence text="7 % versus 22" /><sentence text="9 %; p = 0" /><sentence text="34)" /><sentence text="" /><sentence text="The use of esomeprazole simultaneously with phenprocoumon during hospital admissions might increase the anticoagulant effect"><entity charOffset="11-23" id="DDI-PubMed.26400679.s28.e0" text="esomeprazole" /></sentence><sentence text=" The clinical relevance seems to be limited, because no statistically significant increased risk of overanticoagulation was found" /><sentence text="" /></document>